First-line Pembrolizumab Plus Lenvatinib Plus Belzutifan or MK-1308A Plus Lenvatinib in Advanced RCC: Randomized Open-label Phase 3 LITESPARK-012 Study. Presented by @DrChoueiri @DanaFarber. #ESMO26 written coverage by @rksayyid @UAUrology > https://bit.ly/4yFu33m #KidneyCancer #RCC @myESMO